Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2019; 65(2): 3-11


The increased activity of TIMP-1 in the blood as a predictor of the recurrence of atrial fibrillation in the postoperative period

O.V. Goriachyi1,2, A.I. Gozhenko3, O.M. Levchenko1,2, O.V. Goriacha2

  1. Odessa Regional Clinical Hospital, Odesa, Ukraine
  2. Odessa National Medical University, Odesa, Ukraine
  3. Ukrainian Scientific Research Institute of Transport Medicine, Odesa, Ukraine
DOI: https://doi.org/10.15407/fz65.02.003

Abstract

The purpose of this study was to determine the relationship between tissue inhibitor of metalloproteinases-1 and atrial fibrillation recurrence after catheter ablation. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is involved in extracellular matrix remodeling which is considered to be a marker of regulation of matrix metalloproteinase activity. An enzyme-linked immunosorbent assay prior to a radiofrequency catheter ablation (RFA) procedure was used for measuring the serum level of TIMP-1 in 210 patients: 80 patients without history of atrial fibrillation (AF) and 130 patients with idiopathic AF (paroxysmal AF – 30, persistent AF – 32, long-standing AF – 35 and permanent AF – 33). Their relationship with intraoperative efficacy and recurrence of AF was evaluated throughout the entire observation period. The observation period was 22.2 ± 7.9 months. TIMP-1 level was higher in the groups of patients with AF than in the control group: 131.51 ± 36.40, 149.5±42.7, 151.5 ± 42.7 and 155.9 ± 44.7 ng/ml for paroxysmal, persistent, long-standing and permanent forms of AF. In the control group, TIMP-1 level was 103.6 ± 14.7 ng/ml. TIMP-1 level increased with the progression of AF. A multifactor analysis showed that TIMP-1 level, history of atrial fibrillation and left atrial volume were independent predictors of sinus rhythm recovery and recurrence of AF. An increase in TIMP-1 level in patients with AF has been shown. An increase in TIMP-1 levels was observed as AF progressed. TIMP-1 is prognostic criteria of arrhythmia recurrence after RFA.

Keywords: TIMP-1; recurrence; fibrillation; ablation; matrix.

References

  1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circ 2014; 129:837-47. CrossRef PubMed PubMedCentral
  2.  
  3. Staerk L, Sherer J, Ko D, Benjamin E, Helm R. Atrial Fibrillation epidemiology. Pathophysiol and Clin Outcomes Circ. 2017; 120:1501-17. CrossRef PubMed PubMedCentral
  4.  
  5. Pappone C, Vicedomini G, Augello G, Manguso F, Saviano M, Baldi M, et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol. 2011; 4(6):808-14. CrossRef PubMed
  6.  
  7. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS Expert consensus statement on catheter and surgical Ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and followup, definitions, endpoints, and research trial design. Europace. 2012; 14(4): 528-606. CrossRef PubMed
  8.  
  9. Kabra R, Heist EK, Barrett CD, et al. Incidence and electrophysiologic properties of dissociated pulmonary vein activity following pulmonary vein isolation during catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2010; 21:1338-43. CrossRef PubMed
  10.   Noureldin M., Chen H., Bai D. Functional Characterization of novel atrial fibrillation-linked GJA5 (Cx40) Mutants. Int J Mol Sci. 2018; 19:977 CrossRef PubMed PubMedCentral  
  11. Paramdeep S Dhillon, Rasheda A Chowdhury, Pravina M Patel et al. Relationship Between Connexin Expression and Gap-Junction resistivity in human atrial myocardium. Circ Arrhythm and Electrophysiol. 2014;7:321-29. CrossRef PubMed
  12.  
  13. Norihiro Ueda, Mitsuru Yamamoto, Haruo Honjo, et al. The role of gap junctions in stretch-induced atrial fibrillation. Cardiovasc Res 2014; 104; 364-70. CrossRef PubMed PubMedCentral
  14.  
  15. Takahashi N, Kume O, Wakisaka O, et al. Novel strategy to prevent atrial fibrosis and fibrillation. Circ J 2012; 76: 2318-26. CrossRef PubMed
  16.  
  17. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361-79. CrossRef  
  18. Veidal SS, Nielsen MJ, Leeming DJ, et al. Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model. BMC Res Notes 2012; 5: 686. CrossRef PubMed PubMedCentral
  19.  
  20. Fan D, Takawale A, Lee J, et al. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012; 5: 15. CrossRef PubMed PubMedCentral
  21.  
  22. Renko J, Kalela A, Jaakkola O, et al. Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction. Scand J Clin Lab Invest. 2004; 64:255-61. CrossRef PubMed
  23.  
  24. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 2004;43(5):818-25. CrossRef PubMed
  25.  
  26. Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, et al. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. Int J Cardiol. 2011;152(2):231-6. CrossRef PubMed
  27.  
  28. Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal A, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2014;35(8):501-7. CrossRef PubMed PubMedCentral
  29.  
  30. Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ Arrhythm Electrophysiol. 2014;7(5):841-52. CrossRef PubMed
  31.  
  32. Combes S, Jacob S, Combes N, Karam N, Chaumeil A, Guy-Moyat B, et al. Predicting favourable outcomes in the setting of radiofrequency catheter ablation of longstanding persistent atrial fibrillation: a pilot study assessing the value of left atrial appendage peak flow velocity. Arch Cardiovasc Dis. 2013;106(1):36-43. CrossRef PubMed
  33.  
  34. Lewkowicz J, Knapp M, Tankiewicz-Kwedlo A, Sawicki R, Kaminska M, Waszkiewicz E, et al. MMP-9 in atrial remodeling in patients with atrial fibrillation. Ann Cardiol Angeiol (Paris). 2015. CrossRef PubMed

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2020.